Skip to main content
Science / Explained
Myths, Read Against the EvidenceArticle 15 of 27

Do GLP-1 peptides cause gallbladder problems?

THE NUMBERS

The Wegovy label includes acute gallbladder disease as a warning. The cardiovascular trial of semaglutide (SELECT) put numbers on it: gallbladder events showed up in about 1 in 36 people on the peptide versus about 1 in 43 on placebo. A small but real increase.

THE MECHANISM

The mechanism is biliary chemistry: when body fat drops fast, cholesterol concentration in bile goes up, and slower gut motility lets gallstones form.

The same risk exists with bariatric surgery, very-low-calorie diets, and other rapid-weight-loss methods. The peptide contributes to the conditions; the speed of weight loss is the dominant lever.

What this means

The safety topic is real and well-mapped. The peptide contributes, but the pace of weight loss is what most determines the risk.

The peptide isn't the cause. The speed of the weight loss is.

← Previous
Do GLP-1 peptides damage the liver?
Next →
Do GLP-1 peptides cause pancreatitis?
Related myths

Do GLP-1 peptides damage the liver?

Direct liver injury isn't a primary safety signal for these peptides.

Read more →

Do GLP-1 peptides cause pancreatitis?

Acute pancreatitis is a labeled warning. The absolute rate in trials is low. The symptom pattern is severe persistent abdominal pain.

Read more →

Do GLP-1 peptides damage the kidneys?

Not directly. The kidney risk in the literature runs through severe dehydration from GI symptoms.

Read more →
Keep building trust

Move from the science to the proof, source, and practical questions.

Science next

What is GLP-1?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Are all peptide sources the same? COAs, testing, and traceability

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Science next

Does a certificate of analysis prove a peptide is trustworthy?

Keep the explanation moving with the next evidence-led Science article.

Keep learning

Practical questions

FAQ

Use the FAQ for logistics, safety boundaries, and common buyer questions.

Read the FAQ
References1 sources
  1. See source line · 2026
    Wegovy prescribing information (FDA-approved label), Acute Gallbladder Disease warning. SELECT trial: Lincoff et al. 2023, *New England Journal of Medicine* (PMID 37952131, DOI 10.1056/NEJMoa2307563).
    Source line — see article body

Disclaimer. This article is for educational purposes only and does not constitute medical advice. Peptide signals and their therapeutic applications are complex and context-dependent.